Solid Biosciences Inc. (SLDB) Ownership
SLDB ownership summary
as of October 17, 2026- Institutions
- 107.6% of shares outstanding
- Insiders
- 0.68% of shares outstanding
- Shares outstanding
- 107.2M
- Float
- 64.8M shares available to trade
- Short interest
- 13.49% 12.7M shares short
- Days to cover
- 10.04 short interest down 25.6% vs prior month
- Institutions 107.56%
- Insiders 0.68%
SLDB top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | RA Capital Management, LLC | 11.23% | 12.0M | $66.6M | +2.7M (+28.9%) | June 30, 2026 |
| 2 | Perceptive Advisors LLC | 11.10% | 11.9M | $65.8M | — | June 30, 2026 |
| 3 | Bain Capital Life Sciences Investors, LLC | 9.15% | 9.8M | $54.2M | — | June 30, 2026 |
| 4 | Siren, L.L.C. | 7.17% | 7.7M | $42.5M | — | June 30, 2026 |
| 5 | BlackRock Inc | 6.47% | 6.9M | $38.3M | +2.0M (+39.8%) | June 30, 2026 |
| 6 | FMR Inc | 6.41% | 6.9M | $38.0M | +3.3M (+90.7%) | June 30, 2026 |
| 7 | Armistice Capital, LLC | 3.99% | 4.3M | $23.7M | +1.1M (+33.7%) | June 30, 2026 |
| 8 | State Street Corp | 3.89% | 4.2M | $23.1M | +3.0M (+271.0%) | June 30, 2026 |
| 9 | Jupiter Topco LLC | 3.77% | 4.0M | $22.4M | +4.0M (0.0%) | June 30, 2026 |
| 10 | HHG PLC | 3.74% | 4.0M | $22.2M | +4.0M (0.0%) | March 31, 2026 |
| 11 | Vanguard Capital Management, LLC | 3.74% | 4.0M | $22.2M | +1.3M (+49.9%) | June 30, 2026 |
| 12 | RTW INVESTMENTS, LLC | 3.63% | 3.9M | $21.5M | +3.9M (0.0%) | June 30, 2026 |
| 13 | Deep Track Capital, LP | 3.32% | 3.6M | $19.7M | — | June 30, 2026 |
| 14 | Franklin Templeton Inc | 3.21% | 3.4M | $19.0M | +1.2M (+56.9%) | June 30, 2026 |
| 15 | Citadel Advisors Llc | 2.63% | 2.8M | $15.6M | +218,322 (+8.4%) | June 30, 2026 |
| 16 | Alyeska Investment Group, L.P. | 2.13% | 2.3M | $12.6M | +359 (+0.0%) | June 30, 2026 |
| 17 | Ameriprise Financial Inc | 2.08% | 2.2M | $12.3M | −213,066 (−8.7%) | June 30, 2026 |
| 18 | Vestal Point Capital LP | 2.01% | 2.2M | $11.9M | −2.8M (−56.8%) | June 30, 2026 |
| 19 | Redmile Group, LLC | 1.82% | 1.9M | $10.8M | −63,200 (−3.1%) | June 30, 2026 |
| 20 | Geode Capital Management, LLC | 1.81% | 1.9M | $10.7M | +644,840 (+49.8%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 13 holders added 27.5M shares and 3 cut 3.1M.
SLDB top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 2.94% | 3.1M | $17.4M | — | August 31, 2026 |
| 2 | Franklin Biotechnology Discv A(acc)USD | 2.54% | 2.7M | $15.1M | +100,277 (+3.8%) | August 31, 2026 |
| 3 | Fidelity Select Biotechnology | 2.43% | 2.6M | $14.4M | — | August 31, 2026 |
| 4 | iShares Russell 2000 ETF | 1.83% | 2.0M | $10.9M | −22,656 (−1.1%) | September 30, 2026 |
| 5 | State Street® SPDR® S&P® Biotech ETF | 1.64% | 1.8M | $9.7M | −33,650 (−1.9%) | September 30, 2026 |
| 6 | Columbia Small Cap Growth Inst | 1.64% | 1.8M | $9.7M | — | August 31, 2026 |
| 7 | Franklin Biotechnology Discovery A | 1.37% | 1.5M | $8.1M | +61,928 (+4.4%) | August 31, 2026 |
| 8 | Fidelity Small Cap Index | 0.80% | 863K | $4.8M | +7,918 (+0.9%) | July 31, 2026 |
| 9 | Fidelity Advisor Biotechnology I | 0.63% | 678K | $3.7M | — | August 31, 2026 |
| 10 | iShares Biotechnology ETF | 0.62% | 669K | $3.7M | −5,072 (−0.8%) | September 30, 2026 |
| 11 | Strategic Advisers Fidelity US TtlStk | 0.55% | 592K | $3.3M | +12,748 (+2.2%) | August 31, 2026 |
| 12 | Fidelity Enhanced Small Cap Core ETF | 0.48% | 510K | $2.8M | +1,068 (+0.2%) | September 30, 2026 |
| 13 | Fidelity Series Small Cap Core | 0.47% | 500K | $2.8M | +53,439 (+12.0%) | July 31, 2026 |
| 14 | Columbia Small Cap Value Discv A | 0.42% | 453K | $2.5M | +3,000 (+0.7%) | August 31, 2026 |
| 15 | Vanguard Russell 2000 ETF | 0.42% | 452K | $2.5M | +10,160 (+2.3%) | August 31, 2026 |
| 16 | iShares Russell 2000 Value ETF | 0.34% | 359K | $2.0M | +544 (+0.2%) | September 30, 2026 |
| 17 | iShares Russell 2000 Growth ETF | 0.32% | 344K | $1.9M | −436 (−0.1%) | September 30, 2026 |
| 18 | Fidelity Small Cap Discovery | 0.32% | 341K | $1.9M | +152,416 (+81.0%) | July 31, 2026 |
| 19 | Fidelity Extended Market Index | 0.32% | 339K | $1.9M | −4,916 (−1.4%) | August 31, 2026 |
| 20 | Schwab US Small-Cap ETF™ | 0.31% | 335K | $1.9M | +225 (+0.1%) | September 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
SLDB insider transactions
latest 20| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-18 | David T Howton | Sell | $5.82 | 7,469 | $43,470 |
| 2026-02-18 | Ilan Ganot | Sell | $5.82 | 2,658 | $15,470 |
| 2026-02-18 | Jessie Hanrahan | Sell | $5.82 | 4,134 | $24,060 |
| 2026-02-18 | Kevin Tan | Sell | $5.82 | 5,404 | $31,451 |
| 2026-02-18 | Paul Herzich | Sell | $5.82 | 3,616 | $21,045 |
| 2026-02-18 | Alexander Cumbo | Sell | $5.82 | 16,644 | $96,868 |
| 2026-02-04 | Ilan Ganot | Sell | $6.44 | 7,205 | $46,400 |
| 2026-02-04 | Paul Herzich | Sell | $6.44 | 10,905 | $70,228 |
| 2026-02-04 | Kevin Tan | Sell | $6.44 | 14,783 | $95,203 |
| 2026-02-04 | Jessie Hanrahan | Sell | $6.44 | 12,348 | $79,521 |
| 2026-02-04 | Gabriel Brooks | Sell | $6.44 | 12,616 | $81,247 |
| 2026-02-04 | David T Howton | Sell | $6.44 | 18,894 | $121,677 |
| 2026-02-04 | Alexander Cumbo | Sell | $6.44 | 48,913 | $315,000 |
| 2026-02-02 | David T Howton | Sell | $6.44 | 37,771 | $243,245 |
| 2026-02-02 | Paul Herzich | Sell | $6.44 | 26,250 | $169,050 |
| 2026-02-02 | Paul Herzich | Sell | $6.44 | 26,250 | $169,050 |
| 2026-02-02 | Kevin Tan | Sell | $6.44 | 26,837 | $172,830 |
| 2026-02-02 | Jessie Hanrahan | Sell | $6.44 | 26,535 | $170,885 |
| 2026-02-02 | Jessie Hanrahan | Sell | $6.44 | 26,535 | $170,885 |
| 2026-02-02 | Gabriel Brooks | Sell | $6.44 | 28,335 | $182,477 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
SLDB shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns SLDB
Institutional investors own 107.6% of Solid Biosciences's shares and insiders 0.68%. The largest holder is RA Capital Management, LLC with 11.23% of the shares (12.0M), as of June 30, 2026. Among the top 20 institutions, 13 added shares and 3 reduced their stake in the latest filings. Short interest is 13.49% of the float, or 10.04 days of average trading volume. The share count rose 5,305.5% since 2016.
Related: SLDB analyst forecast, SLDB key metrics. See the SLDB stock overview for the latest quote and news.
SLDB ownership FAQ
Who owns the most Solid Biosciences stock?
The largest shareholders of Solid Biosciences are RA Capital Management, LLC (11.23%), Perceptive Advisors LLC (11.10%), Bain Capital Life Sciences Investors, LLC (9.15%), Siren, L.L.C. (7.17%), BlackRock Inc (6.47%).
What percentage of Solid Biosciences is owned by institutions?
Institutions hold 107.6% of Solid Biosciences's shares outstanding; insiders hold 0.68%.
Which funds own Solid Biosciences?
The largest fund holders of Solid Biosciences are Vanguard MStar Total Stk Mkt Idx Invest (2.94%), Franklin Biotechnology Discv A(acc)USD (2.54%), Fidelity Select Biotechnology (2.43%), iShares Russell 2000 ETF (1.83%), State Street® SPDR® S&P® Biotech ETF (1.64%).
What is Solid Biosciences's short interest?
12.7M shares of Solid Biosciences were sold short, 13.49% of the float; at the average daily volume it would take 10.04 days to cover.
Are insiders buying or selling Solid Biosciences?
Of the latest 20 reported insider transactions in Solid Biosciences (since February 2, 2026), 0 were purchases and 20 were sales.
How many shares of Solid Biosciences are outstanding?
Solid Biosciences has 107.2M shares outstanding, of which 64.8M are in the public float.